Aurdan Capital Management LLC Trims Stake in Thermo Fisher Scientific Inc. $TMO

Aurdan Capital Management LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 67.2% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 1,604 shares of the medical research company’s stock after selling 3,285 shares during the quarter. Aurdan Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $778,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Highline Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 126.9% during the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 33 shares in the last quarter. Capital A Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 825.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after acquiring an additional 66 shares in the last quarter. Cloud Capital Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $31,000. Howard Hughes Medical Institute bought a new stake in Thermo Fisher Scientific during the second quarter valued at about $33,000. Finally, Harbor Asset Planning Inc. bought a new position in Thermo Fisher Scientific in the second quarter worth about $34,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on TMO shares. Argus boosted their target price on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Wells Fargo & Company set a $683.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. JPMorgan Chase & Co. raised their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Leerink Partners upped their price target on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. Finally, Robert W. Baird set a $653.00 price objective on Thermo Fisher Scientific in a research note on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $633.68.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 1,058 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total value of $622,379.08. Following the completion of the sale, the vice president directly owned 13,087 shares in the company, valued at $7,698,558.62. This represents a 7.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Michel Lagarde sold 22,046 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $563.56, for a total transaction of $12,424,243.76. Following the completion of the transaction, the chief operating officer directly owned 84,117 shares in the company, valued at $47,404,976.52. This trade represents a 20.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 114,292 shares of company stock worth $66,518,754 over the last three months. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Down 4.1%

Thermo Fisher Scientific stock opened at $541.94 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The stock has a market capitalization of $203.61 billion, a PE ratio of 30.55, a price-to-earnings-growth ratio of 3.26 and a beta of 0.93. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. The business has a 50 day simple moving average of $591.73 and a 200-day simple moving average of $541.12.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, topping the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The company had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.95 billion. During the same quarter in the previous year, the firm earned $6.10 EPS. The firm’s revenue was up 7.2% compared to the same quarter last year. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share repurchase plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board of directors believes its shares are undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.